| Decitabine-and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network X Gu, R Tohme, B Tomlinson, N Sakre, M Hasipek, L Durkin, C Schuerger, ... Leukemia 35 (4), 1023-1036, 2021 | 85 | 2021 |
| PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation X Gu, F Enane, R Tohme, C Schuerger, T Radivoyevitch, Y Parker, ... Cell reports 36 (12), 2021 | 17 | 2021 |
| A first-in-class inhibitor of ISWI-mediated (ATP-dependent) transcription repression releases terminal-differentiation in AML cells while sparing Normal hematopoiesis A Kishtagari, KP Ng, C Jarman, AD Tiwari, JG Phillips, C Schuerger, ... Blood 132, 216, 2018 | 13 | 2018 |
| Mapping Biosafety Level-3 Laboratories by Publications AP C Schuerger, S Abdulla Center for Security and Emerging Technology, 2022 | 5* | 2022 |
| Safeguarding Mail-Order DNA Synthesis in the Age of Artificial Intelligence S Batalis, C Schuerger, GK Gronvall, ME Walsh Applied Biosafety 29 (2), 79-84, 2024 | 4 | 2024 |
| Developing Science and Technology Policy Fellowships in State Governments without Full-Time Legislatures MA Diasio, DF DaCrema, RB Dudek, CR Harris, MN Schmehl, ... Journal of Science Policy & Governance 16 (1), 2020 | 4 | 2020 |
| Understanding the Global Gain-of-Function Research Landscape AP C Schuerger, S Batalis, K Quinn, R Kinoshita, O Daniels Center for Security and Emerging Technology, 2023 | 3* | 2023 |
| China and Medical AI C Schuerger, V Venkatram, K Quinn | 2 | 2024 |
| Viral Families and Disease X: A Framework for US Pandemic Preparedness Policy C Schuerger, S Batalis, K Quinn, A Adalja, A Puglisi | 1 | 2023 |
| White Paper: Developing Science and Technology Policy Fellowships in State Governments without Full-Time Legislatures M Diasio, D DaCrema, R Dudek, C Harris, M Schmehl, C Schuerger, ... Journal of Science Policy & Governance, 1-13, 2020 | 1 | 2020 |
| FLT3-ITD Degrades CEBPA Via the Ubiquitin-Proteosome Pathway X Gu, ZAM Zahran, N Sakre, C Schuerger, Y Saunthararajah Blood 140 (Supplement 1), 2993-2994, 2022 | | 2022 |
| Policy Position: Science Policy Through CL Schuerger, DF DaCrema, MA Diasio, RB Dudek, CR Harris, ... Journal of Science Policy & Governance 20 (01), 2022 | | 2022 |
| Oncogenic disruption and therapeutic restoration of FOXA1 pioneer transcription factor function in bladder cancer CL Schuerger Case Western Reserve University, 2022 | | 2022 |
| Advancing non-cytotoxic DNMT1-targeting to treat chemorefractory pancreatic cancer R Tohme, F Enane, C Schuerger, X Gu, M Fishel, J Pink, D Lindner, ... Cancer Research 81 (13_Supplement), 1088-1088, 2021 | | 2021 |
| Abstract A20: Disruption and restoration of pioneer transcription factor function in bladder cancer C Schuerger, X Gu, Y Parker, D Lindner, B Jha Clinical Cancer Research 26 (15_Supplement), A20-A20, 2020 | | 2020 |
| Disruption and restoration of pioneer transcription factor function in bladder cancer. C Schuerger, X Gu, Y Parker, D Lindner, B Jha CLINICAL CANCER RESEARCH 26 (15), 41-42, 2020 | | 2020 |
| Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network X Gu, R Tohme, B Tomlinson, M Hasipek, L Durkin, C Schuerger, ... bioRxiv, 2020.02. 20.958405, 2020 | | 2020 |
| Abstract C58: p53/p16-independent cytoreduction of chemoresistant pancreatic adenocarcinoma by metabolically optimized epigenetic therapy R Tohme, X Gu, AE Desoky, C Schuerger, D Lindner, D Sohal, ... Cancer Research 79 (24_Supplement), C58-C58, 2019 | | 2019 |
| p53/p16-independent cytoreduction of chemoresistant pancreatic adenocarcinoma by metabolically optimized epigenetic therapy R Tohme, X Gu, A El Desoky, C Schuerger, D Lindner, D Sohal, ... CANCER RESEARCH 79 (24), 2019 | | 2019 |
| Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine X Gu, R Tohme, BK Tomlinson, L Durkin, C Schuerger, AM Zidan, ... Blood 134, 537, 2019 | | 2019 |
